Novartis Investigative Site

Svitavy, Czech Republic 568 25

0 studies enrolling now · 6 studies all time

What they study most

Atherosclerosis, Cardiovascular Disease and Lipoprotein(a), Diabetes Mellitus and Heart Failure, Heart Failure With Preserved Ejection Fraction, Nasal Polyps

Studies at this site

• Lipoprotein(a) in Patients With Cardiovascular Disease (CVD) — Completed
• A Randomized, Double-blind Controlled Study Comparing LCZ696 to Medical Therapy for Comorbidities in HFpEF Patients — Completed
• Study of Efficacy of Fevipiprant in Patients With Nasal Polyposis and Asthma — Completed
• Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction — Completed
• Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events) — Completed
• A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart Failure — Stopped early